The Clinical Trials Core Facility (CTCF) facilitates clinical research at the Case CCC by providing the highest quality infrastructure that includes nursing, regulatory, data management, quality assurance, budgeting and contracting, informatics, and education functions for research staff and investigators. With its expertise in coordinating and managing complex studies including early phase and investigator-initiated trials, the CTCF plays a central role in Case CCC clinical research. The CTCF resides within the Case CCC Clinical Research Office (CRO). The CRO oversees and coordinates all clinical research administration components including the CTCF, Protocol Review and Monitoring System, Data and Safety Monitoring, and Protocol Specific Research Support. As a consortium cancer center, the CTCF oversees operations at the affiliated medical centers, through the Clinical Trials Unit (CTU) at each hospital which is responsible for the development, conduct, and management of specific clinical trials. All training and audits are coordinated through the CTCF. The Medical Director of the CTCF oversees integration of activities of the consortium member CTUs, with standardization ensured through a single policies and procedures manual and monthly meetings of the Clinical Research Operations Committee (C-ROC) and its subcommittee, the Clinical Trials Working Group (CTWG). In 2011, 1,527 patients were enrolled onto Case CCC interventional trials, including 919 patients on therapeutic studies. Thirty-eight percent of accruals to therapeutic intervention studies were to investigator-initiated trials (peer-reviewed, institutional). The CTCF provides support for all cancer clinical trials, from protocol development through reporting of results. The Core also oversees use of the OnCore clinical trials database, ensuring timely maintenance of protocol status and patient accrual.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Levinson, Kimberly L; Jernigan, Amelia M; Flocke, Susan A et al. (2016) Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis 20:47-51
Cooper, Gregory S; Kou, Tzuyung D; Schluchter, Mark D et al. (2016) Changes in Receipt of Cancer Screening in Medicare Beneficiaries Following the Affordable Care Act. J Natl Cancer Inst 108:
Wiechert, Andrew; Saygin, Caner; Thiagarajan, Praveena S et al. (2016) Cisplatin induces stemness in ovarian cancer. Oncotarget 7:30511-22
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2016) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev :
Kenyon, Jonathan; Nickel-Meester, Gabrielle; Qing, Yulan et al. (2016) Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. Int J Stem Cell Res Ther 3:
Dowlati, A; Lipka, M B; McColl, K et al. (2016) Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 27:642-7
Markowitz, Sanford D; Nock, Nora L; Schmit, Stephanie L et al. (2016) A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One 11:e0146435
Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72
Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:
Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633

Showing the most recent 10 out of 1148 publications